"On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech," said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. Read more on their experience: bit.ly/4hX3Ecm $PDSB

John Dawson, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience as the Company advances PDS0301 toward Ph. 3 trial in mCRC and PDS0101 toward potential partnerships. bit.ly/4hX3Ecm $PDSB

PDS Biotech today announced the appointments of three accomplished pharma industry executives, John Dawson, Deborah Ramsdell, and Bruce Wendel, to the Company’s Board of Directors. Read more: bit.ly/4hX3Ecm $PDSB

Tomorrow at 8 AM, Jonathan M. Hernandez, M.D. from @theNCI, will join $PDSB management to discuss clinical outcomes from the PDS0301 Ph. 2 trials for the treatment of advanced liver-associated cancers, with a focus on the mCRC cohort. Register here: bit.ly/4zhWy83

PDS Biotech will host a virtual KOL event on Oct. 15 at 8 a.m. ET featuring Jonathan M. Hernandez, M.D., of @theNCI. Dr. Hernandez will join company management to discuss PDS0301 Ph. 2 clinical outcomes in advanced liver-associated cancers, with a focus on mCRC. bit.ly/4zhWy83 $PDSB

Data recently published in JAMA Oncology from a Phase 2 trial of PDS0101 showed a median overall survival of 39.3 months in first-line (1L), recurrent/metastatic (R/M), immune checkpoint inhibitor (ICI)-naïve patients. Read more about the results: bit.ly/3T3cP1f $PDSB

Kirk Shepard, M.D., PDS Biotech Chief Medical Officer, comments on the publication of VERSATILE-002 Ph.2 clinical trial results in JAMA Oncology, evaluating PDS0101 in combination with pembrolizumab in HPV16-positive R/M head and neck cancer: bit.ly/4yrViPP $PDSB

Results from a Phase 2 trial of $PDSB’s HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab were recently published in JAMA Oncology. PDS Biotech continues to prioritize PDS0301 in mCRC while pursuing a partnership strategy for PDS0101. bit.ly/4yrViPP

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors: bit.ly/4dzHKJi $PDSB

PDS Biotech announces up to $22.55M in equity funding in a PIPE transaction. In connection, Dr. Patrick Soon-Shiong, M.D., will join $PDSB's Board. The Company expects the PIPE will advance development of PDS0301 into late-stage clinical development. bit.ly/4xJ7v29

PDS Biotech Reports Second Quarter 2026 Financial Results: bit.ly/4cDCrrP $PDSB

PDS Biotech has announced a strategic refocus prioritizing the advancement of PDS0301 in metastatic colorectal cancer (mCRC) while pursing strategic partnership opportunities for PDS0101. Read the Letter to Shareholders from CEO Frank Bedu-Addo, Ph.D.: bit.ly/4i0MDOC $PDSB

PDS Biotech will host a conference call and webcast today at 8:00 am ET to report financial results for the quarter and year ended March 31, 2026, and provide a clinical programs and corporate update. Join the webcast here: bit.ly/4wf8Gpo $PDSB

Frank Bedu-Addo, PhD, President and CEO of PDS Biotech, comments on the clinical and regulatory progress made in the first quarter 2026: bit.ly/4uCFTtw $PDSB

PDS Biotech today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. Read more: bit.ly/4uCFTtw $PDSB

PDS Biotech will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am ET. For details: bit.ly/4f5ulu4 $PDSB

April is #HeadAndNeckCancerAwarenessMonth. HPV is fueling a rise in these cancers, and patients deserve better treatment options. At PDS Biotech, we are seeking to deliver a novel and promising targeted immunotherapy for HPV16-driven head and neck cancers. Learn more: bit.ly/3X0FUsN

Head and neck cancers are expected to impact nearly 73,000 Americans this year, according to @theNCI. Early detection can save lives. Learn more about how to spot the symptoms from @CDCgov: bit.ly/3Ouls2k #HeadAndNeckCancerAwarenessMonth

Trials of PDS01ADC were performed in unresectable MSS or pMMR colorectal liver metasteses, which constitute the majority of mCRC, and in which immune checkpoint inhibitors have been unsuccessful. Read more on our positive Stage 1 interim Ph. 2 data: bit.ly/4ceHUWA $PDSB

PDS Biotech CEO Frank Bedu-Addo, PhD. comments on the positive PDS01ADC interim Phase 2 clinical trial data from Stage 1 of NCI-led metastatic colorectal cancer (mCRC) trial: bit.ly/4ceHUWA $PDSB